BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

17032

539871

THYROCARE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

THYROCARE TECH LTD performance

Today’s low

Today’s high

₹ 872.10 ₹ 900.00
₹ 878.10

52 week low

52 week high

₹ 571.40 ₹ 1055.00
₹ 878.10

Open Price

₹ 889.90

Prev. Close

₹ 890.25

Volume (Shares)

75414.00

Total traded value

₹ 662.21

Upper Circuit

₹ 1068.30

Lower Circuit

₹ 712.20

info

THYROCARE TECH LTD Share Price Update

As of the latest trading session, THYROCARE TECH LTD share price is currently at ₹ 878.1, which is down by ₹ -12.15 from its previous closing. Today, the stock has fluctuated between ₹ 872.10 and ₹ 900.00. Over the past year, THYROCARE TECH LTD has achieved a return of 36.15 %. In the last month alone, the return has been 21.67 %. Read More...

THYROCARE TECH LTD fundamentals


  • Market cap (Cr)

    4,649.77

  • P/E Ratio (TTM)

    48.56

  • Beta

    0.41

  • Book Value / share

    101.35

  • Return on equity

    13.75%

  • EPS (TTM)

    18.07

  • Dividend yield

    2.39%

  • Net profit/quarter (Cr)

    21.95

info icon alternate text
  • Market cap (Cr)

    4,633.35

  • P/E Ratio (TTM)

    48.56

  • Beta

    0.37

  • Book Value / share

    101.35

  • Return on equity

    13.75%

  • EPS (TTM)

    18.07

  • Dividend yield

    2.39%

  • Net profit/quarter (Cr)

    21.95

info icon alternate text

THYROCARE TECH LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 173.87
Operating Expense 130.60
Net Profit 21.95
Net Profit Margin (%) 12.62
Earnings Per Share (EPS) 4.08
EBITDA 60.18
Effective Tax Rate (%) 54.07
Particulars DEC 2024 (Values in Cr)
Revenue 152.55
Operating Expense 128.12
Net Profit 19.10
Net Profit Margin (%) 12.52
Earnings Per Share (EPS) 3.53
EBITDA 43.76
Effective Tax Rate (%) 31.63
Particulars SEP 2024 (Values in Cr)
Revenue 163.05
Operating Expense 124.83
Net Profit 29.59
Net Profit Margin (%) 18.14
Earnings Per Share (EPS) 5.59
EBITDA 50.91
Effective Tax Rate (%) 26.64
Particulars JUN 2024 (Values in Cr)
Revenue 143.63
Operating Expense 111.66
Net Profit 25.15
Net Profit Margin (%) 17.51
Earnings Per Share (EPS) 4.75
EBITDA 45.51
Effective Tax Rate (%) 28.42
Particulars MAR 2024 (Values in Cr)
Revenue 141.23
Operating Expense 118.99
Net Profit 19.23
Net Profit Margin (%) 13.61
Earnings Per Share (EPS) 3.63
EBITDA 36.40
Effective Tax Rate (%) 23.23
Particulars MAR 2025 (Values in Cr)
Revenue 633.10
Operating Expense 495.23
Net Profit 95.78
Net Profit Margin (%) 15.12
Earnings Per Share (EPS) 17.95
EBITDA 200.36
Effective Tax Rate (%) 36.65
Particulars MAR 2024 (Values in Cr)
Revenue 524.02
Operating Expense 432.98
Net Profit 71.14
Net Profit Margin (%) 13.57
Earnings Per Share (EPS) 13.44
EBITDA 141.06
Effective Tax Rate (%) 27.57
Particulars MAR 2023 (Values in Cr)
Revenue 486.46
Operating Expense 410.78
Net Profit 56.97
Net Profit Margin (%) 11.71
Earnings Per Share (EPS) 10.77
EBITDA 117.39
Effective Tax Rate (%) 29.72
Particulars MAR 2022 (Values in Cr)
Revenue 561.53
Operating Expense 361.55
Net Profit 152.05
Net Profit Margin (%) 27.07
Earnings Per Share (EPS) 28.75
EBITDA 238.23
Effective Tax Rate (%) 26.68
Particulars MAR 2021 (Values in Cr)
Revenue 474.27
Operating Expense 325.27
Net Profit 119.77
Net Profit Margin (%) 25.25
Earnings Per Share (EPS) 22.66
EBITDA 183.01
Effective Tax Rate (%) 25.73
Particulars MAR 2024 (Values in Cr)
Book Value / Share 93.02
ROE % 13.10
ROCE % 17.92
Total Debt to Total Equity 0.06
EBITDA Margin 25.97
Particulars MAR 2023 (Values in Cr)
Book Value / Share 97.37
ROE % 12.13
ROCE % 16.86
Total Debt to Total Equity 0.04
EBITDA Margin 25.09
Particulars MAR 2022 (Values in Cr)
Book Value / Share 99.54
ROE % 33.05
ROCE % 41.39
Total Debt to Total Equity 0.03
EBITDA Margin 40.79
Particulars MAR 2021 (Values in Cr)
Book Value / Share 80.82
ROE % 28.50
ROCE % 36.66
Total Debt to Total Equity 0.03
EBITDA Margin 37.12
Particulars MAR 2020 (Values in Cr)
Book Value / Share 69.39
ROE % 22.05
ROCE % 33.82
Total Debt to Total Equity 0.02
EBITDA Margin 40.11
Particulars MAR 2024 (Values in Cr)
Book Value / Share 90.58
ROE % 13.75
ROCE % 18.63
Total Debt to Total Equity 0.06
EBITDA Margin 27.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 94.86
ROE % 10.94
ROCE % 15.73
Total Debt to Total Equity 0.04
EBITDA Margin 24.60
Particulars MAR 2022 (Values in Cr)
Book Value / Share 98.43
ROE % 31.48
ROCE % 41.64
Total Debt to Total Equity 0.03
EBITDA Margin 42.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 84.26
ROE % 29.08
ROCE % 37.49
Total Debt to Total Equity 0.02
EBITDA Margin 38.59
Particulars MAR 2020 (Values in Cr)
Book Value / Share 71.58
ROE % 24.88
ROCE % 35.60
Total Debt to Total Equity 0.01
EBITDA Margin 42.98
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 39.89
Total Assets 643.88
Total Liabilities 643.88
Total Equity 527.63
Share Outstanding 52952676
Price to Book Ratio 6.54
Return on Assets (%) 10.98
Return on Capital (%) 12.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 28.47
Total Assets 632.72
Total Liabilities 632.72
Total Equity 535.22
Share Outstanding 52930043
Price to Book Ratio 4.53
Return on Assets (%) 10.19
Return on Capital (%) 12.05
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 13.91
Total Assets 607.66
Total Liabilities 607.66
Total Equity 526.57
Share Outstanding 52903332
Price to Book Ratio 7.86
Return on Assets (%) 28.98
Return on Capital (%) 33.45
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 15.73
Total Assets 545.80
Total Liabilities 545.80
Total Equity 427.28
Share Outstanding 52871371
Price to Book Ratio 10.72
Return on Assets (%) 20.73
Return on Capital (%) 26.48
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 11.07
Total Assets 470.88
Total Liabilities 470.88
Total Equity 366.65
Share Outstanding 52833000
Price to Book Ratio 6.92
Return on Assets (%) 18.77
Return on Capital (%) 23.95
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 34.10
Total Assets 620.27
Total Liabilities 620.27
Total Equity 513.81
Share Outstanding 52952676
Price to Book Ratio 6.54
Return on Assets (%) 11.46
Return on Capital (%) 13.33
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 16.39
Total Assets 611.87
Total Liabilities 611.87
Total Equity 521.04
Share Outstanding 52930043
Price to Book Ratio 4.53
Return on Assets (%) 9.31
Return on Capital (%) 10.93
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 12.00
Total Assets 597.17
Total Liabilities 597.17
Total Equity 520.70
Share Outstanding 52903332
Price to Book Ratio 7.86
Return on Assets (%) 25.46
Return on Capital (%) 29.2
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 7.67
Total Assets 527.79
Total Liabilities 527.79
Total Equity 445.46
Share Outstanding 52874419
Price to Book Ratio 10.72
Return on Assets (%) 22.69
Return on Capital (%) 26.89
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 7.30
Total Assets 442.39
Total Liabilities 442.39
Total Equity 378.23
Share Outstanding 52836000
Price to Book Ratio 6.92
Return on Assets (%) 17.92
Return on Capital (%) 20.97
Particulars MAR 2024 (Values in Cr)
Net Income 95.59
Cash from Operations 196.61
Cash from Investing -91.28
Cash from Financing -84.81
Net change in Cash -8.47
Free Cash Flow 258.19
Particulars MAR 2023 (Values in Cr)
Net Income 87.41
Cash from Operations 157.77
Cash from Investing -38.99
Cash from Financing -86.18
Net change in Cash 4.14
Free Cash Flow 201.42
Particulars MAR 2022 (Values in Cr)
Net Income 227.90
Cash from Operations 170.17
Cash from Investing -23.57
Cash from Financing -89.41
Net change in Cash 0.43
Free Cash Flow 208.00
Particulars MAR 2021 (Values in Cr)
Net Income 152.54
Cash from Operations 157.94
Cash from Investing -48.66
Cash from Financing -61.58
Net change in Cash 4.49
Free Cash Flow 184.63
Particulars MAR 2020 (Values in Cr)
Net Income 146.48
Cash from Operations 212.39
Cash from Investing 0.95
Cash from Financing -164.78
Net change in Cash 4.05
Free Cash Flow 222.29
Particulars MAR 2024 (Values in Cr)
Net Income 98.22
Cash from Operations 184.18
Cash from Investing -80.29
Cash from Financing -83.71
Net change in Cash -8.81
Free Cash Flow 227.45
Particulars MAR 2023 (Values in Cr)
Net Income 81.07
Cash from Operations 148.72
Cash from Investing -31.65
Cash from Financing -87.50
Net change in Cash 0.87
Free Cash Flow 169.84
Particulars MAR 2022 (Values in Cr)
Net Income 207.38
Cash from Operations 162.00
Cash from Investing -12.32
Cash from Financing -86.91
Net change in Cash 6.45
Free Cash Flow 202.41
Particulars MAR 2021 (Values in Cr)
Net Income 161.28
Cash from Operations 154.66
Cash from Investing -53.09
Cash from Financing -57.81
Net change in Cash 0.17
Free Cash Flow 193.76
Particulars MAR 2020 (Values in Cr)
Net Income 156.33
Cash from Operations 180.58
Cash from Investing 26.84
Cash from Financing -162.65
Net change in Cash 0.52
Free Cash Flow 189.56
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 76.41 13.35 100103.60 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 83.30 12.22 100103.60 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00

THYROCARE TECH LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
878.10 -1.36 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 868.90
  • 26 Days 775.40
  • 10 Days 830.90
  • 50 Days 765.70
  • 12 Days 819.00
  • 100 Days 785.60
  • 20 Days 787.70
  • 200 Days 784.30
897.77 PIVOT

First Support

876.53

First Resistance

911.48

Second Support

862.82

Second Resistance

932.72

Third Support

841.58

Third Resistance

946.43

RSI

68.52

ADX

38.64

MACD

43.61

Williams % R

-23.29

Commodity Channel Index (CCI)

119.40

Date

2025-04-30

Week

168884.00

Same Day

26878.00

Month

64915.00

1 Year

0.42

3 Year

0.45

Over 1 Month

21.67%

down

Over 1 Year

36.15%

down

Over 3 Months

12.98%

down

Over 3 Years

4.43%

down

Over 6 Months

-7.51%

down

Over 5 Years

11.53%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

THYROCARE TECH LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
11.56%
Promoter Holdings
71.05%
FII
2.4%
DII
14.96%
Promoter Shares(Pledge Percentage)
100.0%
Name Shares Category
Docon Technologies Private Limited 3.7656092E7 (71.06%) Shareholding of Promoter and Promoter Group
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund 3736556.0 (7.05%) Public Shareholding
Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund 1403955.0 (2.65%) Public Shareholding
Quant Mutual Fund - Quant Small Cap Fund 1040157.0 (1.96%) Public Shareholding
Dsp India T.i.g.e.r. Fund 646377.0 (1.22%) Public Shareholding
Api Holdings Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

THYROCARE TECH LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Apr 2023 18.0 Interim 20 Apr 2023 Equity shares
11 May 2022 15.0 Interim 12 May 2022 Equity shares
17 Jun 2021 15.0 Final 19 Jun 2021 Equity shares
12 Nov 2020 10.0 Interim 13 Nov 2020 Equity shares
21 Nov 2019 5.0 Interim 22 Nov 2019 Equity shares
14 Aug 2019 20.0 Final 18 Aug 2019 Equity shares
02 Aug 2018 5.0 Final 04 Aug 2018 Equity shares
15 Feb 2018 5.0 Interim 16 Feb 2018 Equity shares
03 Aug 2017 5.0 Final 06 Aug 2017 Equity shares
08 Feb 2017 5.0 Interim 09 Feb 2017 Equity shares
01 Sep 2016 2.5 Final 05 Sep 2016 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Apr 2023 18.0 Interim 20 Apr 2023 Equity shares
11 May 2022 15.0 Interim 12 May 2022 Equity shares
17 Jun 2021 15.0 Final 19 Jun 2021 Equity shares
12 Nov 2020 10.0 Interim 13 Nov 2020 Equity shares
21 Nov 2019 5.0 Interim 22 Nov 2019 Equity shares
14 Aug 2019 20.0 Final 18 Aug 2019 Equity shares
02 Aug 2018 5.0 Final 04 Aug 2018 Equity shares
15 Feb 2018 5.0 Interim 16 Feb 2018 Equity shares
03 Aug 2017 5.0 Final 06 Aug 2017 Equity shares
08 Feb 2017 5.0 Interim 09 Feb 2017 Equity shares
01 Sep 2016 2.5 Final 05 Sep 2016 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

THYROCARE TECH LTD Share Price

Thyrocare Technologies Limited was incorporated in January, 2000. The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.

As of 31 March 2024, the Company offered 929 distinct tests and 90 profiles of tests to detect a number of disorders, including thyroid disorders, growth disorders, metabolism disorders, auto-immunity, diabetes, anemia, cardiovascular disorders, infertility and various infectious diseases. Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests. The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs). The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

Nueclear Healthcare Limited (NHL), the wholly owned subsidiary of Thyrocare Technologies, is engaged in PET-CT Scan imaging diagnostic business. NHL currently has 10 active operating PET-CT scanners in 8 imaging centers: two in Navi Mumbai, two in New Delhi, one each in Hyderabad, Central Mumbai, Western Mumbai, Baroda, Nashik and Bangalore. NHL also owns and operates a medical cyclotron unit in Navi Mumbai, which produces the radioactive biomarker FDG required for PET-CT scanning.

Thyrocare Technologies CPL, which is located in Navi Mumbai, is equipped with automated systems, diagnostic testing instruments and processes from leading international and Indian healthcare brands. The CPL is fully automated and driven by a barcoded and bi-directionally interfaced system and Laboratory information system.

Thyrocare Technologies collects samples through a pan-India network of authorized service providers comprised of Thyrocare Service Providers (TSPs), Thyrocare Aggregators (TAGs) and Online Clients (OLCs), who in turn source these samples from local hospitals, laboratories, diagnostic centers, nursing homes, clinics and doctors that avail diagnostic services from the company. As of 31 March 2019, Thyrocare Technologies had a network of 6342 authorized service providers, comprised of 578 TAGs, 529 TSPs and 5235 OLCs spread across 555 cities and 32 states and 2 union territories. The wide spread network of authorized service providers has enabled the company to expand the reach of the CPL and RPLs, thereby providing the company with access to a larger customer base.

Thyrocare Technologies promoted Nueclear Healthcare Limited (NHL) in the year 2011. Thyrocare Technologies acquired controlling stake Nueclear Healthcare Limited effective 15 November 2014. Thyrocare Technologies commenced setting up Regional Processing Laboratories (RPLs) in 2014.

During the financial year ended 31 March 2016, Thyrocare Technologies issued 31,87,562 equity shares at a premium of Rs. 295.95/- per share, towards consideration for acquiring 46,11,000 equity shares of M/s. Nueclear Healthcare Limited from remaining six shareholders, so that it becomes wholly-owned subsidiary of the company. NHL became wholly-owned subsidiary of the company with effect from 16 December 2015.

The increase in revenue of Thyrocare Technologies' diagnostic services business in Fiscal 2016 was mainly on account of increased focus on preventive care offerings, improvement in turnaround time by newly set-up regional processing laboratories, enhancement in the brand awareness, realization of revenue from newly introduced verticals and media campaigns, and growth in the company's imaging business.

Thyrocare Technologies came out with an Initial Public Offer (IPO), to fulfill its contractual obligation to one of the overseas PE Investor to give an exit route within the agreed time. A total number of 1,07,44,708 equity shares were offered for sale to the public at an Issue Price of Rs. 446. The Issue opened on April 27, 2016 and closed on April 29, 2016 and it was a grand success with an over-subscription of more than 75 times, the highest in healthcare industry in India. Subsequently, the company got stellar listing on the bourses on 9 May 2016 with stock prices zooming more than 45% of the higher price band of share price within a few minutes of commencement of trading in the stock exchanges.

During the year financial year ended 31 March 2017, Thyrocare Technologies decided to sell its entire holding in Thyrocare International Holding Company (TIHC) at the acquisition cost to a related party, but it could not be completed for want of approval of Reserve Bank of India. Thyrocare Technologies has been holding 5,440 equity shares in Thyrocare International Holding Company (TIHC), Mauritius, valued at Rs 16.15 million, which is about 9.09% of the total equity share capital of the said company. TIHC is holding 51% of the equity share capital of Thyrocare Gulf Laboratories WLL, Bahrain.

The increase in revenue of Thyrocare Technologies' diagnostic services business in Fiscal 2017 was mainly on account of the growth in revenue from preventive care offerings, sustained growth in seek care business by improvement in turnaround time due to newly set-up regional processing laboratories, recognition of brand Aarogyam, realization of revenue from newly introduced verticals and media campaigns. The revenue from imaging business in Fiscal 2017, however, grew at lesser pace than the pathology business, mainly on account stagnation of growth evidenced in some region, limitation on conducting scan due to non-availability of FDG for conducting the investigations, delay in starting of PETCT centres in Vadodra and Raipur and competition in regional market.

During the financial year ended 31 March 2018, Thyrocare Technologies invested Rs.20 crore in the equity share capital of Equinox Labs Private Limited (Equinox), a company engaged in the business of water, food and other environment and hygiene testing. While Rs. 10 crores were paid by cash, for another Rs.10 crore, Thyrocare Technologies transferred its Water Testing business, on a slump sale basis, valued at Rs.10 crore. Equinox has issued 4,29,185 numbers of equity shares of the company, constituting 30% of their paid-up Equity Share capital and Thyrocare Technologies is entitled to have two directors as nominees on their Board. Thus, Equinox became an Associate company of Thyrocare Technologies, as defined in the Companies Act, 2013.

During the year under review, Thyrocare Technologies' revenue from imaging business grew at rapid pace than the pathology business, mainly on account of newly added PETCT centers ramping up operations and gaining market control in the respective regions.

During the year 2019, the Company bought back 9,58,900 equity shares for an aggregate amount of Rs 63 crore being 1.78% of the total paid-up equity share capital, at an average price of Rs 656.90 per equity share. The equity shares bought back were extinguished on 12 October 2018 and 22 October 2018.

In FY 2019, the Company has given Loan aggregating to Rs 39 Crores to Nueclear Healthcare Limited under the provisions of Section 186 of the Companies Act, 2013, read with Companies (Meetings of Board and its Powers) Rules, 2014.

The Company's businesses have been adversely impacted due to the rapid spread of novel coronavirus (COVID-19) pandemic across the globe. In view of the countrywide lockdown, operations of the Company's / Group's (collection centres, imaging centres, CPLs, RPLs and offices, etc.) are scaled down or shut down from the second half of March 2020. Although the lockdown has been lifted either partially or fully in some of the states, its duration in remaining states is still uncertain. The business of Nueclear Healthcare Limited(a whollyowned subsidiary) has also been adversely impacted.

As on 31 March 2020, the company has 1 wholly owned subsidiary, Nueclear Healthcare Limited and 1 associate company, Equinox Labs Private Ltd.

As of 31 March 2021, the Company offered 279 distinct tests and 79 profiles of tests to detect a number of disorders, including thyroid disorders, growth disorders, metabolism disorders, auto-immunity, diabetes, anemia, cardiovascular disorders, infertility and various infectious diseases.

On September 02, 2021, Docon Technologies Private Limited acquired 3,49,72,999 equity shares having a face value of Rs. 10/- each from erstwhile promoters, Dr. A. Velumani and Mr. A. Sundararaju and 9 other promoter group shareholders after complying with the statutory requirements as provided under SEBI . Docon also acquired additional 26,83,093 equity shares having face value of Rs. 10/- each from public through the open offer made by them pursuant to the provisions of SEBI (SAST) Regulations. Thus, Docon Technologies Private Limited acquired a total no of 3,76,56,092 equity shares representing 71.22% of total paid up capital of Company and has become new promoter of the Company. Consequently, the Company has become a subsidiary company of Docon Technologies Private Limited w.e.f. September 02, 2021.

As on, March 31, 2022, the Company had a network of about 1500 active channel partners and more than 9000 collection points, comprised of TSPs, TAGs, OLCs, local hospitals, laboratories, diagnostic centres, nursing homes, clinics and doctors spread across more than 500 districts covering all the states within the country.

During year 2022, the Company provided an extensive menu of over 700 tests, of which more than 300 tests have been added in FY 22.
To further enhance its quality, the Company installed automation for urine testing at 12 lab locations, Beckman Analysers in Zonal Processing Laboratories for specialized tests.

In 2022-23, Company increased the number of labs accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) from 6 to 20. It extended the flagship preventive care series 'Aarogyam' with Pro and Plus series. The introduction of the plus and pro series in the flagship 'Aarogyam' package took a preventive care segment to new heights with the launch of 24x7 non-fasting packages and launched a new series of Investigation packages under the brand 'Jaanch.

In 2023-24, Thyrocare entered into a Joint Venture Agreement to set up lab operations in Tanzania, which became operational from April, 2024. On February 27, 2024, Company acquired 100% stake in Think Health Diagnostics Private Limited to enter into ECG at home services. The Company increased the number of labs accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) from 15 to 25 in 2024. It launched Troponin I Heart Attack Risk Test for the first time in India to understand the risk of heart attack with a single blood test.

Parent organization Indian Private
NSE symbol THYROCARE
Founded 2000
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Thyrocare Technologies Ltd?

Answer Field

The share price of Thyrocare Technologies Ltd for NSE is ₹ 878.1 and for BSE is ₹ 875.

What is the Market Cap of Thyrocare Technologies Ltd?

Answer Field

The market cap of Thyrocare Technologies Ltd for NSE is ₹ 46,49.77 Cr. and for BSE is ₹ 46,33.35 Cr. as of now.

What is the 52 Week High and Low of Thyrocare Technologies Ltd?

Answer Field

The 52 Week High and Low of Thyrocare Technologies Ltd for NSE is ₹ 1055.00 and ₹ 571.40 and for BSE is ₹ 1053.05 and ₹ 570.75.

How to Buy Thyrocare Technologies Ltd share?

Answer Field

You can trade in Thyrocare Technologies Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Thyrocare Technologies Ltd?

Answer Field

The 1 year returns on the stock has been 36.15%.

What is the Current Share Price of Thyrocare Technologies Ltd?

Answer Field

Thyrocare Technologies Ltd share price is for NSE ₹ 878.1 & for BSE ₹ 875 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Thyrocare Technologies Ltd Share?

Answer Field

The market cap of Thyrocare Technologies Ltd for NSE ₹ 46,49.77 & for BSE ₹ 46,33.35 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Thyrocare Technologies Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Thyrocare Technologies Ltd share is 48.56.

What is the PB ratio of Thyrocare Technologies Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Thyrocare Technologies Ltd share is 101.35.

How to Buy Thyrocare Technologies Ltd Share?

Answer Field

You can trade in Thyrocare Technologies Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Thyrocare Technologies Ltd Share on Bajaj Broking App?

Answer Field

To buy Thyrocare Technologies Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Thyrocare Technologies Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|